SCHEMBL13626337

SCHEMBL13626337

CCN1CCc2c(cccc2-c2ccccc2)C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.62
DHPS P49366 2/20 0.56
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
MAPT P10636 2/20 0.53
DRD2 P14416 1/20 0.53
DRD4 P21917 1/20 0.53
DRD3 P35462 1/20 0.53
HRH3 Q9Y5N1 1/20 0.48
POLB P06746 1/20 0.47
PARP10 Q53GL7 1/20 0.45
PARP11 Q9NR21 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
LMNA P02545 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
ALDH1A1 P00352 4/20 0.42
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13180847 0.81 HTT (0.45) HTTDHPSDRD2DRD4DRD3
SCHEMBL5807575 0.81 HTT (0.54) HTTDHPSMEN1KMT2AMAPT
SCHEMBL5840128 0.80 HTT (0.56) HTTDHPSMEN1KMT2AMAPT
SCHEMBL8357272 0.80 POLB (0.49) HTTDHPSMEN1KMT2ADRD2
SCHEMBL5809501 0.78 HTT (0.54) HTTDHPSMEN1KMT2AMAPT
SCHEMBL13626332 0.77 HRH3 (0.54) HTTDRD2DRD4DRD3HRH3
SCHEMBL13611933 0.76 PARP10 (0.45) HTTDHPSDRD2DRD4DRD3
SCHEMBL179076 0.76 HTT (0.51) HTTDRD2DRD4DRD3ALDH1A1
SCHEMBL29438739 0.76 HTT (0.51) HTTDRD2DRD4DRD3ALDH1A1
SCHEMBL31386901 0.75 HTT (0.52) HTTDHPSMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090291998-A1 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF EISAI R&D MANAGEMENT CO., LTD. 2009-11-26 US disclosed
US-7524883-B2 Eponemycin and epoxomicin analogs and uses thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291998-A1 EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF PSMC4, PSMB6, EPOR HTT 3135/4885DHPS 1280/4885MEN1 1973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.